The Discounted Cash Flow (DCF) valuation of Y-mAbs Therapeutics, Inc (YMAB) is (50.52) USD. With the latest stock price at 8.61 USD, the upside of Y-mAbs Therapeutics, Inc based on DCF is -686.7%.
Based on the latest price of 8.61 USD and our DCF valuation, Y-mAbs Therapeutics, Inc (YMAB) is a sell. selling YMAB stocks now will result in a potential gain of 686.7%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.1% - 6.4% | 5.7% |
| Long-term Growth Rate | 3.0% - 4.8% | 3.9% |
| Fair Price | (364.17) - (27.24) | (50.52) |
| Upside | -4329.6% - -416.3% | -686.7% |